SYH2072
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 16, 2026
A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets
(clinicaltrials.gov)
- P1 | N=112 | Recruiting | Sponsor: InnovStone Therapeutics Limited
First-in-human • New P1 trial
1 to 1
Of
1
Go to page
1